Holen Sie sich die Stockscreener-App
28.93
6.31%
1.6578
Alumis Inc Aktie (ALMS) Neueste Nachrichten
[144] ALUMIS INC. SEC Filing - Stock Titan
Price to sales forward of Alumis Inc. – NASDAQ:ALMS - TradingView
Form 4 Alumis Inc For: 2 July By Investing.com - Investing.com Canada
Alumis (ALMS) director Lynn Tetrault receives RSU and stock option awards - Stock Titan
Director at ALUMIS (NASDAQ: ALMS) receives RSU and option grants - Stock Titan
[Form 4] ALUMIS INC. Insider Trading Activity - Stock Titan
Alumis (ALMS) director awarded new RSUs and stock options - Stock Titan
Alumis (ALMS) director Akkaraju receives RSUs, options and reports fund stakes - Stock Titan
Form 13D/A Alumis Inc. For: 2 July By Investing.com - Investing.com Nigeria
Alumis (ALMS) major holder keeps 15.1M-share stake as ownership hits 12.3% - Stock Titan
[8-K] ALUMIS INC. Reports Material Event - Stock Titan
Stifel and Guggenheim Stay Bullish on Alumis (ALMS) - Insider Monkey
Enterprise value to EBITDA forward of Alumis Inc. – NASDAQ:ALMS - TradingView
Wells Fargo Maintains Alumis(ALMS.US) With Buy Rating, Maintains Target Price $51 - Moomoo
Enterprise value to revenue forward of Alumis Inc. – NASDAQ:ALMS - TradingView
Alumis Inc.(NasdaqGS: ALMS) added to Russell 2500 Growth Benchmark - marketscreener.com
ALMS Forecast — Price Target — Prediction for 2027 - TradingView
Alumis Inc.(NasdaqGS: ALMS) dropped from Russell Microcap Value Benchmark Index - marketscreener.com
Alumis Unveils Breakthrough TYK2 Inhibitors: Leading Clinical Results in Psoriasis and Lupus, $180B+ Market Opportunity by 2030 318 – Minichart - Minichart
Alumis Inc.(NasdaqGS: ALMS) dropped from Russell 2000 Value Benchmark - marketscreener.com
Alumis updates corporate presentation highlighting envudeucitinib Phase 3 wins, SLE and NDA timing - TradingView
Alumis (NASDAQ: ALMS) posts updated June 2026 corporate presentation - Stock Titan
Alumis Inc.(NasdaqGS: ALMS) added to Russell 2000 Growth Benchmark - marketscreener.com
Alumis (ALMS) Is Up 7.3% After Russell Reclassifies It Into Growth Indices What’s Changed - simplywall.st
Alumis Inc.(NasdaqGS: ALMS) dropped from Russell 3000E Value Benchmark - marketscreener.com
Oppenheimer Maintains Alumis(ALMS.US) With Buy Rating, Maintains Target Price $55 - Moomoo
Alumis: Is Envudeucitinib The 'Real Deal?' We Should Find Out Soon - Seeking Alpha
Alumis Inc. Actuals & Estimates (BOATS:ALMS) - TradingView
Alumis | 4: Statement of changes in beneficial ownership of securities-10% Owner Foresite Capital Management VI LLC - Moomoo
Alumis Inc. (ALMS) Sees Modest Gain as Stock Consolidates Near ResistanceETF Liquidity - dars.gov.et
Alumis Inc (ALMS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Alumis Inc (ALMS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Alumis Inc (ALMS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Alumis Inc (ALMS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Alumis Inc (ALMS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Alumis Inc (ALMS) Institutional Confidence - TradingKey
ALMS Q1 2026 Earnings: Narrower-than-Expected Loss Lifts SharesROIC Trend Report - dars.gov.et
Alumis Inc (ALMS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Alumis Inc (ALMS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Alumis Inc (ALMS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Alumis Stock Sinks As Revenue Shock Jolts Hopes - TipRanks
ALMS Q1 2026 Earnings: EPS Beat Drives 15.55% Stock SurgeRevenue Warning Signal - newsline.com
Alumis | ARS: Annual Report to Security Holders - Moomoo
Alumis (ALMS) Sees 10.3% Surge, Reaching $23.06 - GuruFocus
ALUMIS INC (ALMS) Stock Chart - ChartMill
Alumis Shares Surge 16% as Traders Eye New Drug Move - TechStock²
Why Alumis Inc. Shares Are Suddenly Climbing - TipRanks
ALMS Q1 2026 Earnings: Narrower-Than-Expected Loss Propels Stock HigherMargin Compression Risk - newsline.com
Alumis | SCHEDULE 13D/A: Others - Moomoo
ACT CAPITAL MANAGEMENT, LLC's Alumis Inc(ALMS) Holding History - GuruFocus
Why Alumis Inc. Stock Is Sinking So Sharply - TipRanks
ALMS Q1 2026 Earnings: EPS Surprises to the Upside Amid Pre-Revenue Clinical StagePre-Earnings Drift - newsline.com
Has Alumis's Envudeucitinib Redefined Psoriasis Treatment - Kavout
Analyst Sentiment On Alumis (ALMS) Remains Strong Following Q1 Results And Envudeucitinib Pipeline Advancements - Insider Monkey
ALMS Q1 2026 Earnings: EPS Beat Partially Offsets Investor ConcernsProfit Cycle Analysis - The Legal Advocate
Alumis (ALMS) Chief Medical Officer exercises stock options for 26,852 shares - Stock Titan
ALMSAlumis Inc Stock Price and Quote - Finviz
10 Under-the-Radar Stocks with Massive Upside for 2026 - Insider Monkey
TOWERVIEW LLC's Alumis Inc(ALMS) Holding History - GuruFocus
Alumis Inc. (ALMS) Q1 2026 Earnings: Narrower Loss Mirrors Operational Discipline, Pre-Revenue Stage PersistsEPS Guidance Update - The Legal Advocate
Alumis Inc. (ALMS) Edges Lower, Consolidating Above Key Support LevelWyckoff Distribution - newsline.com
How Alumis’ Revenue Slide but Smaller Per-Share Loss Will Impact Alumis (ALMS) Investors - simplywall.st
Alumis | S-3ASR: Automatic shelf registration statement of securities of well-known seasoned issuers - Moomoo
Alumis Analyst Ratings and Price Targets | NASDAQ:ALMS - Benzinga
1.21%
3.14%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):